Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, Integrated DNA Technologies to Codevelop Clinical NGS Solutions

NEW YORK (GenomeWeb) – Sophia Genetics said this week that it is partnering with Integrated DNA Technologies to provide customers with target capture and data analytics for next-generation sequencing-based clinical diagnostics.

Under the terms of the agreement, the partners will combine the Sophia DDM analytics platform with IDT's hybridization-based target enrichment panels. The combined solution will address the needs of European hospitals that are moving from small panels of 1–20 genes to medium panels with 21–200 genes, according to Sophia. The first bundled solution to launch will be for diagnosing hereditary cancers such as breast, ovarian, and colon cancers. Future solutions will target leukemia and cardiac disease.

"The NGS bundle solutions are a true game changer for hospitals, relieving them of the burden of testing multiple NGS enrichment technologies, " Sophia CEO Jurgi Camblong said in a statement. "Having evaluated a large number of DNA enrichment technologies, we can now offer hospitals validated solutions that combine best-in-class target enrichment products with our advanced machine-learning based analytics. This will simplify validation of future NGS tests to meet hospitals' needs for high quality diagnostics."

The combined offering will initially be available to more than 120 hospitals that currently use Sophia DDM with additional clients to follow in the coming months.